Actinium Pharmaceuticals Interest Expense 2011-2026 | ATNM

Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.

Includes:

Interest on bank loans
Interest on corporate bonds
Interest on leases
Interest on credit lines and overdrafts

High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.

Low interest expenses with high profits are a sign of financial stability.

Annual Interest Expense Actinium Pharmaceuticals

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-	-	-	1.09 M	190 K	178 K	172 K	173 K	5.43 K	5.01 K	7.87 K	866	2.51 K	-1.1 M	-4.76 K

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
1.09 M	-1.1 M	59.8 K

Quarterly Interest Expense Actinium Pharmaceuticals

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-	-	-	-	927 K	-	1.08 M	461 K	547 K	-	325 K	83 K	35 K	-	46 K	54 K	52 K	-	73 K	37 K	13 K	-	53 K	59 K	29 K	-	49.2 K	50 K	30.3 K	-	-	-	-	-	666	1.68 K	2.66 K	-	588	1.55 K	5.73 K	-	-	-	-	-	1.3 K	634	575	-	319 K	321 K	313 K	-1.32 K	-3.59 K	2.51 K	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
1.08 M	-3.59 K	146 K

Interest Expense of other stocks in the Biotechnology industry

Issuer	Interest Expense	Price	% 24h	Market Cap	Country
Applied Genetic Technologies Corporation AGTC	2.67 M	-	-	$ 26.5 M	USA
MorphoSys AG MOR	4.66 M	-	2.43 %	$ 254 M	Germany
Allakos ALLK	8 K	-	-	$ 28.6 M	USA
Advaxis ADXS	28 K	-	-9.65 %	$ 45.9 M	USA
Akouos AKUS	-1.72 M	-	0.23 %	$ 488 M	USA
AlloVir ALVR	1.44 M	-	4.14 %	$ 49.1 M	USA
I-Mab IMAB	722 K	-	-	$ 866 M	China
Aeglea BioTherapeutics AGLE	29.5 M	-	-	$ 1.01 B	USA
Ampio Pharmaceuticals AMPE	-5.01 K	-	-11.43 %	$ 502 K	USA
Genfit SA GNFT	4.68 M	-	2.54 %	$ 160 B	France
ACADIA Pharmaceuticals ACAD	1.82 M	$ 22.2	-2.07 %	$ 3.68 B	USA
Applied Molecular Transport AMTI	-4 K	-	-	$ 10.1 M	USA
Galapagos NV GLPG	1.03 M	$ 27.86	-1.97 %	$ 2.69 B	Belgium
AIkido Pharma AIKI	-5.79 M	-	1.93 %	$ 17.4 M	USA
Applied Therapeutics APLT	-27 K	-	-	$ 8.42 M	USA
Aptinyx APTX	737 K	-	-39.0 %	$ 4.57 M	USA
ImmuCell Corporation ICCC	349 K	$ 8.44	1.08 %	$ 76.2 M	USA
Innoviva INVA	16.7 M	$ 23.05	-2.7 %	$ 1.55 B	USA
Innate Pharma S.A. IPHA	440 K	$ 1.49	6.43 %	$ 235 M	France
Avenue Therapeutics ATXI	294 K	-	-52.27 %	$ 4.45 M	USA
Jaguar Health JAGX	67 K	$ 0.23	-6.64 %	$ 536 K	USA
AgeX Therapeutics AGE	51 K	-	-10.17 %	$ 12.2 K	USA
Aravive ARAV	2.84 M	-	-13.39 %	$ 1.45 M	USA
Atreca BCEL	3 K	-	-11.76 %	$ 5.79 M	USA
BioNTech SE BNTX	14.2 M	$ 101.57	-0.48 %	$ 27.2 B	Germany
Brainstorm Cell Therapeutics BCLI	-93 K	-	-2.5 %	$ 5.88 M	USA
BioDelivery Sciences International BDSI	-6 K	-	-4.8 %	$ 255 M	USA
Aquestive Therapeutics AQST	6.55 M	$ 4.05	-0.98 %	$ 433 M	USA
Arcutis Biotherapeutics ARQT	443 K	$ 22.37	-3.95 %	$ 2.85 B	USA
Fennec Pharmaceuticals FENC	441 K	$ 6.26	-6.57 %	$ 179 M	USA
Autolus Therapeutics plc AUTL	36.7 M	$ 1.41	-4.73 %	$ 375 M	Britain
Can-Fite BioPharma Ltd. CANF	227 K	$ 2.98	2.41 %	$ 4.91 M	Israel
Madrigal Pharmaceuticals MDGL	-463 K	$ 518.58	0.37 %	$ 11.6 B	USA
BeiGene, Ltd. BGNE	-42.6 M	-	0.49 %	$ 251 B	Cayman-islands
Akero Therapeutics AKRO	4.67 M	-	-	$ 3.67 B	USA